阿司匹林抵抗的研究进展及中西医结合研究方向

作者	单位
鹿小燕	中日友好医院全国中西医结合心血管病中心
徐浩	中日友好医院全国中西医结合心血管病中心
陈可冀	中日友好医院全国中西医结合心血管病中心
廖文强	中日友好医院全国中西医结合心血管病中心

摘要点击次数: 1421

全文下载次数: 601

中文摘要:

阿司匹林是最经典的抗血小板药物,以其优异的效价比,在人类心脑血管病防治方面发挥着重要作用,然而其抗血小板作用个体差异很大,约25%～40%存在阿司匹林抵抗(aspirin resistance,AR),严重影响了其干预效果,已成为一个备受关注的临床问题。笔者认为,从长期服用抗血小板剂量阿司匹林的心脑血管病患者中筛选AR患者,从线粒体基因组单核苷酸多态性(MtSNP)寻找其基因差异位点,可为临床及早预测AR并制定合理干预策略奠定基础;同时运用均匀设计优化方法 ,对AR患者的血小板进行体外干预,探索防治AR抗血小板中药的最佳配伍组合和配比关系,发挥中药复方多靶点干预特点,可为临床研发防治AR的有效复方中药制剂提供新的思路。

英文摘要:

Aspirin is the most classic anti-platelet drug,plays its important role in preventing and treating cardio-and cerebro-vascular diseases for its excellent potency ratio; however,there exists individual difference in its anti-platelet effect,aspirin resistance (AR) presented in about 25%-40% of patients,which seriously influences the intervention effect of aspirin. So AR has become a clinical problem that attached more attention. In this paper,the authors put forward a new thinking for clinical studying and inventing new effective Chinese drugs on AR by means of screen out AR suffered from cardio/cerebro-vascular patients long-term received aspirin; find their gene difference sites from MtSNP to establish a foundation for AR predication and reasonable strategy formation; meantime,through platelet intervention in vitro adopting uniform design optimization method to explore the best compatibility and matching relationship of anti-platelet Chinese medicine for AR prevention and treatment,so as to fully display the multi-target intervening effects of Chinese drug-therapy.

关闭